Navigation Links
Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
Date:2/21/2008

DAYTRANA that was launched last year, represented 32% of our fourth quarter product sales.

The acquisition of New River Pharmaceuticals gave us full ownership and control of VYVANSE, and this new generation ADHD treatment is establishing itself in the US, where it has already gained a market share of 6%(i). The launch of VYVANSE continues to progress well and we are confident about the medication's future growth supported by new clinical studies and expected additional indications. Our total ADHD franchise has now grown to 32% of the total US ADHD market, compared to 28% at the end of 2006, extending our leadership position in this specialist area.

We've also acquired five pipeline compounds in new technologies and new markets, by licensing the marketing and co-development rights to a range of both biological and small molecule products from Renovo, Amicus Therapeutics and Alba Therapeutics.

Looking forward, we will continue to execute our strategy, which has provided good returns for shareholders, by building on the success of our growing specialist drugs portfolio focused on the treatment of symptomatic diseases. We currently expect 2008 revenue growth to be in the mid to high teens range and positive revenue growth through 2010."

(i) per IMS weekly prescription data at February 8, 2008

Product Highlights

- VYVANSE(TM) - Attention Deficit and Hyperactivity Disorder ("ADHD").

- Approved by the US Food and Drug Administration ("FDA") for use in the pediatric population in February 2007 and launched in the US in July 2007 (dosage strengths 30mg, 50mg and 70mg).

- On December 10, 2007 the FDA approved three additional dosage strengths (20mg, 40mg and 60mg) which will be available in retail pharmacies in the US in the second quarter of 2008. These additional strengths are designed to increase dosing flexibility.

- By February 15, 2008 VYVANSE had achieved a US ADHD market share of 6.3% based on daily presc
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Correction Re Website
2. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
3. Shire Engages Palio
4. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
5. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
6. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire plc: Board Changes
9. David Mott Appointed Non Executive Director at Shire
10. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
11. Shire Divests Non-Core Product Portfolio to Almirall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 Research and Markets ... Technology Market - Global Industry Analysis, Size, Share, Growth, ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... acids (either DNA or RNA) into cells. This technology ... cancer cells and protein metabolism by affecting the nuclear ...
(Date:7/11/2014)... July 11, 2014 Cayenne Medical, ... specializing in the soft tissue reconstruction segment, announced ... System for surgeries involving the shoulder and extremities. ... a novel, inserter-controlled deployment method. The unique delivery ... deployment, anchor pull-out, or anchor displacement (also commonly ...
(Date:7/10/2014)... July 10, 2014 Terascala, the industry ... that Alan Swahn, a former vice president of product ... as vice president of marketing. Terascala’s software when combined ... NetApp create the highest performance and most reliable solutions ... to guide Terascala’s channel expansion and broaden its product ...
(Date:7/10/2014)... Senior supply chain management executives from over ... challenges of “Reducing Cost, Lead Time, & Defects in ... Describing the partnership of the Bio Supply Management Alliance ... ( SCMI) of the University of San Diego ... Kroc Institute of Peace and Justice in San Diego, ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Terascala Expands Executive Team 2Terascala Expands Executive Team 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4
... , Collaboration with Biomodels facilitates development ... Sept. 16 Avaxia Biologics, Inc., a biotechnology company developing oral ... that it has been awarded a Phase I SBIR grant from ... development of a novel antibody therapeutic for oral mucositis. , ...
... Sealers, cleaners, and ... , ... 16, 2009 - Tile Media Properties (TMP), best known for The Tile Doctor brand and ... The 10 year-old Atlanta-based company receives millions of unique visitors annually and is well-recognized as ...
... DIEGO, Sept. 16 Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ), a ... will be speaking at the UBS Global Life Sciences Conference. The details ... September 22, 2009, Time: 2:30pm Eastern, ... Graham Cooper, Chief Financial Officer, , , ...
Cached Biology Technology:Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis 2Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis 3The Tile Doctor Launches Inaugural Product Line 2The Tile Doctor Launches Inaugural Product Line 3
(Date:7/11/2014)... burning in eastern New South Wales, Australia when NASA,s ... 03:35 UTC on July 11 (12:35 p.m. local time/11:35 ... eastern New South Wales (NSW), the Moderate Resolution Imaging ... the region and spotted smoke (light brown) from various ... are outlined in red. , The New South Wales, ...
(Date:7/11/2014)... scientists have set a "mouse TRAP" to capture the ... recent study published in the Journal of Clinical ... technique called TRAP to extract cellular and genetic information ... scientists at the Rockefeller Institute for Medical Research in ... protein-making machinery, or ribosomes, of the cell type of ...
(Date:7/11/2014)... team of researchers, including scientists from the Max Planck ... reported a major step in understanding photosynthesis, the process ... the oxygen in its atmosphere and which is therefore ... , The researchers report the first direct visualization ... the step in which a specific protein complex, photosystem ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2
... common condition affecting 12-20 percent of Americans age 65 ... heart attack and strokeand many with the disease may ... Interventional Radiology. For more than a decade, the ... Life, has helped identify this very serious and potentially ...
... , This press release is available in German . ... as defined by the EU Water Framework Directive is unlikely to ... a study in which data from the four largest rivers in ... analysed over ten years. The study was carried out by the ...
... Agriculture (USDA) aerial photography survey of 38,000 wildfire-burned acres ... first evidence that the invasive leafy spurge weed is ... Booth, a rangeland specialist with the Agricultural Research Service ... the survey using a technique he developed called Very ...
Cached Biology News:Interventional radiologists: Learn about peripheral arterial disease and get moving 2Interventional radiologists: Learn about peripheral arterial disease and get moving 3Poor outlook for water quality in Germany 2Digital cameras open new view of America's West 2
... Green II RNA gel stain is ... has bright fluorescence when bound to RNA ... ideal for use with either formaldehyde/agarose or ... UV transilluminators. A 500 µL unit size ...
... SYBR Green II RNA gel stain ... has bright fluorescence when bound to RNA and ... use with either formaldehyde/agarose or polyacrylamide gels using ... stains 100 minigels. A 500 µL unit size ...
... EIA Principle: Glutathion-S-transferases (GST) ... are involved in the detoxification processes. ... subgroups: Alpha, Mu, Pi, Teta and ... physiochemical, immunological, enzymatic and s Sample ...
... Microarrays designed for RNA aptamer screening and ... and powerful Paraflo microfluidic on-chip synthesis platform. ... our comprehensive DNA/RNA Aptamer Microarray Service. ... RNA Aptamer Microarray contains greater than 1500 ...
Biology Products: